|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.0900 - 0.1089|
|52 Week Range||0.0750 - 4.2751|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
* Proceeds support the development of lead asset, RT-AR001, an adenosine receptor antagonist * Funds were secured from an existing institutional investor WESTLAKE VILLAGE, CA / ACCESSWIRE / January 12, 2021 / Inspyr Therapeutics, Inc. (OTC PINK:NSPX), a pharmaceutical company focused on the research and development of novel targeted precision therapeutics for the treatment of cancer, announces the sale of $500,000 of a senior convertible debenture ("Debenture") from an existing institutional investor to pursue the research and development of the company's novel portfolio of adenosine receptor antagonists and for general corporate purposes.
* Expansion of patent portfolio of novel adenosine immuno-modulator compoundsWESTLAKE VILLAGE, CA / ACCESSWIRE / December 10, 2020 / Inspyr Therapeutics, Inc.